Crinetics Pharmaceuticals Inc. discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. All our programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance our programs to become commercially successful products.
Endocrine Drug Discovery: Our internal discovery programs are focused on endocrine drugs that provide objective biomarker endpoints early in clinical development, and in some cases as registration endpoints. All targets have a rapid, low cost development path to early value creating data and provide significant clinical advances in large markets.
Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases